Tempest Therapeutics (NASDAQ: TPST) registers 8.27M shares for resale by sellers
Tempest Therapeutics (NASDAQ: TPST) has registered 8,268,495 shares of common stock for resale by existing selling stockholders. These shares were issued as consideration in an Asset Purchase Agreement dated November 19, 2025, for the acquisition of CAR-T and related assets. The company will not receive any proceeds from these resales, which will be conducted by the named selling stockholders, including Matthew Angel and Lotus Capital (BVI) Limited.
How this was made

The 30-second read
Why it matters
This event is primarily a liquidity and share supply adjustment, with limited immediate impact on company fundamentals.
Market read
While relevant to current shareholders and traders, the event has limited broader market impact.
What to watch
Market reaction may be muted if the resale is well-absorbed by existing shareholders; also, the absence of proceeds to the company limits fundamental concerns.
Background
Tempest Therapeutics registered over 8 million shares for resale by existing shareholders, related to an asset acquisition completed in late 2025.
Ticker impact
High relevance due to recent share registration and acquisition activity.
Potential short-term downward pressure due to increased share availability; long-term impact depends on subsequent use of proceeds and company performance.
The event is factual and indicates no direct capital influx to the company, but the increased supply could influence stock price dynamics in the near term.
Market effects
Limited sector impact; biotech/pharma sectors may experience minor volatility due to share dilution concerns.
Minimal regional impact; event is company-specific.
Negligible global relevance.
Counterpoint
The share registration could be viewed positively if it signals upcoming strategic initiatives or partnerships, leading to potential stock appreciation in the longer term.
Key entities
- CompanyTempest Therapeutics
A biotech company focused on developing novel cancer therapies.
- IndividualMatthew Angel
A significant shareholder involved in the resale.
- Institutional InvestorLotus Capital (BVI) Limited
A major shareholder involved in the resale.




